Difference between revisions of "Penile cancer"
m (→References) |
(added regimen & variant labels) |
||
Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
+ | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
+ | |- | ||
+ | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | ||
+ | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
+ | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Adjuvant chemotherapy= | =Adjuvant chemotherapy= | ||
− | ==TIP== | + | ==TIP {{#subobject:4c1bc6|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "it is reasonable to give [[#TIP|4 courses of TIP]] in the adjuvant setting if it was not given preoperatively and the pathology shows high-risk features." (see neoadjuvant chemotherapy section) | No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "it is reasonable to give [[#TIP|4 courses of TIP]] in the adjuvant setting if it was not given preoperatively and the pathology shows high-risk features." (see neoadjuvant chemotherapy section) | ||
− | ==TPF (Docetaxel)== | + | ==TPF (Docetaxel) {{#subobject:118691|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
TPF: '''<u>T</u>'''axotere, '''<u>P</u>'''latinol, '''<u>F</u>'''luorouracil | TPF: '''<u>T</u>'''axotere, '''<u>P</u>'''latinol, '''<u>F</u>'''luorouracil | ||
− | ===Regimen, Necchi et al. 2011=== | + | ===Regimen, Necchi et al. 2011 {{#subobject:a57146|Variant=1}}=== |
''Necchi et al. 2011 is a case report.'' | ''Necchi et al. 2011 is a case report.'' | ||
Line 34: | Line 47: | ||
=Neoadjuvant chemotherapy= | =Neoadjuvant chemotherapy= | ||
− | ==TIP== | + | ==TIP {{#subobject:fe995|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
TIP: '''<u>T</u>'''axol, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol | TIP: '''<u>T</u>'''axol, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol | ||
− | ===Regimen, Pagliaro et al. 2010=== | + | ===Regimen, Pagliaro et al. 2010 {{#subobject:b81dfa|Variant=1}}=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 53: | Line 70: | ||
*[[Mesna (Mesnex)]] 200 mg/m2 IV given twice, at 4 and 8 hours after each dose of ifosfamide | *[[Mesna (Mesnex)]] 200 mg/m2 IV given twice, at 4 and 8 hours after each dose of ifosfamide | ||
− | '''21 to 28-day cycles x 4 cycles; "cycle was repeated on day 22 if the patient's absolute neutrophil count was at least 1,400/ | + | '''21 to 28-day cycles x 4 cycles; "cycle was repeated on day 22 if the patient's absolute neutrophil count was at least 1,400/µL and platelet count was at least 100,000/µL"''' |
Supportive medications: | Supportive medications: | ||
Line 68: | Line 85: | ||
# Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/24/3851.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20625118 PubMed] | # Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/24/3851.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20625118 PubMed] | ||
− | ==VBM== | + | ==VBM {{#subobject:fdb0db|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate | VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate | ||
− | ===Regimen, Pizzocaro et al. 1988 & Pagliaro et al. 2009=== | + | ===Regimen, Pizzocaro et al. 1988 & Pagliaro et al. 2009 {{#subobject:a25051|Variant=1}}=== |
''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ||
Line 95: | Line 116: | ||
=Metastatic or unresectable disease= | =Metastatic or unresectable disease= | ||
− | ==BMP, MPB== | + | ==BMP, MPB {{#subobject:ab9e5f|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol | BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol | ||
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol, '''<u>B</u>'''leomycin | <br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol, '''<u>B</u>'''leomycin | ||
− | ===Regimen #1, Haas et al. 1999 (SWOG 8520)=== | + | ===Regimen #1, Haas et al. 1999 (SWOG 8520) {{#subobject:8938|Variant=1}}=== |
''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ||
Line 121: | Line 146: | ||
*Furosemide (Lasix) 40 mg IV once prior to cisplatin | *Furosemide (Lasix) 40 mg IV once prior to cisplatin | ||
− | ===Regimen #2, Corral et al. 1998 & Pagliaro et al. 2009=== | + | ===Regimen #2, Corral et al. 1998 & Pagliaro et al. 2009 {{#subobject:99e731|Variant=1}}=== |
''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ''The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."'' | ||
Line 145: | Line 170: | ||
# '''Review''': Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. doi: 10.1007/s00345-008-0310-z. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007%2Fs00345-008-0310-z link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18682961 PubMed] | # '''Review''': Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. doi: 10.1007/s00345-008-0310-z. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007%2Fs00345-008-0310-z link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18682961 PubMed] | ||
− | ==Cisplatin & Fluorouracil== | + | ==Cisplatin & Fluorouracil {{#subobject:f70357|Regimen=1}}== |
− | ===Regimen, Shammas et al. 1992=== | + | {| class="wikitable" style="float:right; margin-left: 5px;" |
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
+ | ===Regimen, Shammas et al. 1992 {{#subobject:1e2b1c|Variant=1}}=== | ||
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 163: | Line 192: | ||
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/1538445 PubMed] | # Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/1538445 PubMed] | ||
− | ==Cisplatin & Irinotecan== | + | ==Cisplatin & Irinotecan {{#subobject:606813|Regimen=1}}== |
− | ===Regimen, Theodore et al. 2008 (EORTC 30992)=== | + | {| class="wikitable" style="float:right; margin-left: 5px;" |
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
+ | ===Regimen, Theodore et al. 2008 (EORTC 30992) {{#subobject:ec3985|Variant=1}}=== | ||
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 186: | Line 219: | ||
# Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [http://annonc.oxfordjournals.org/content/19/7/1304.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18417462 PubMed] | # Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [http://annonc.oxfordjournals.org/content/19/7/1304.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18417462 PubMed] | ||
− | ==Paclitaxel (Taxol)== | + | ==Paclitaxel (Taxol) {{#subobject:3bde8f|Regimen=1}}== |
− | ===Regimen, Di Lorenzo et al. 2011=== | + | {| class="wikitable" style="float:right; margin-left: 5px;" |
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
+ | ===Regimen, Di Lorenzo et al. 2011 {{#subobject:2565c5|Variant=1}}=== | ||
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 207: | Line 244: | ||
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [http://www.sciencedirect.com/science/article/pii/S0302283811008967 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21871710 PubMed] | # Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [http://www.sciencedirect.com/science/article/pii/S0302283811008967 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21871710 PubMed] | ||
− | ==Panitumumab (Vectibix)== | + | ==Panitumumab (Vectibix) {{#subobject:92a67f|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, Necchi et al. 2011=== | + | ===Regimen, Necchi et al. 2011 {{#subobject:7d9cd7|Variant=1}}=== |
''Necchi et al. 2011 is a case report referenced by the NCCN Guidelines, Penile Cancer version 1.2013.'' | ''Necchi et al. 2011 is a case report referenced by the NCCN Guidelines, Penile Cancer version 1.2013.'' | ||
Line 227: | Line 268: | ||
# Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. doi: 10.1200/JCO.2011.34.8367. Epub 2011 May 31. [http://jco.ascopubs.org/content/29/22/e650.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21632506 PubMed] | # Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. doi: 10.1200/JCO.2011.34.8367. Epub 2011 May 31. [http://jco.ascopubs.org/content/29/22/e650.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21632506 PubMed] | ||
− | ==TIP== | + | ==TIP {{#subobject:2169d9|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "[[#TIP|TIP]] is a reasonable first-line treatment for patients with metastatic penile cancer." (see neoadjuvant chemotherapy section) | No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "[[#TIP|TIP]] is a reasonable first-line treatment for patients with metastatic penile cancer." (see neoadjuvant chemotherapy section) | ||
− | ==TPF (Paclitaxel)== | + | ==TPF (Paclitaxel) {{#subobject:edc2a7|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
TPF: '''<u>T</u>'''axol, '''<u>P</u>'''latinol, '''<u>F</u>'''luorouracil | TPF: '''<u>T</u>'''axol, '''<u>P</u>'''latinol, '''<u>F</u>'''luorouracil | ||
− | ===Regimen, Pizzocaro et al. 2009=== | + | ===Regimen, Pizzocaro et al. 2009 {{#subobject:5f8356|Variant=1}}=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span |
Revision as of 06:39, 9 February 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
9 regimens on this page
10 variants on this page
|
Adjuvant chemotherapy
TIP
back to top |
No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "it is reasonable to give 4 courses of TIP in the adjuvant setting if it was not given preoperatively and the pathology shows high-risk features." (see neoadjuvant chemotherapy section)
TPF (Docetaxel)
back to top |
TPF: Taxotere, Platinol, Fluorouracil
Regimen, Necchi et al. 2011
Necchi et al. 2011 is a case report.
Level of Evidence: Case report
- Docetaxel (Taxotere) 75 mg/m2 IV once on day 1
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 750 mg/m2/day IV continuous infusion on days 1 to 4
21-day cycles x 3 cycles
References
- Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. doi: 10.1200/JCO.2011.34.8367. Epub 2011 May 31. link to original article contains verified protocol PubMed
Neoadjuvant chemotherapy
TIP
back to top |
TIP: Taxol, Ifosfamide, Platinol
Regimen, Pagliaro et al. 2010
Level of Evidence: Phase II
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
- Ifosfamide (Ifex) 1200 mg/m2 IV over 2 hours once per day on days 1 to 3
- Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3
- Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
- Mesna (Mesnex) 400 mg/m2 IV once before each dose of ifosfamide
- Mesna (Mesnex) 200 mg/m2 IV given twice, at 4 and 8 hours after each dose of ifosfamide
21 to 28-day cycles x 4 cycles; "cycle was repeated on day 22 if the patient's absolute neutrophil count was at least 1,400/µL and platelet count was at least 100,000/µL"
Supportive medications:
- After cisplatin, hydration with 3 liters of a solution of 5% dextrose, sodium chloride, potassium chloride, magnesium sulfate, and mannitol
- Either Dexamethasone (Decadron) 8 mg IV once 1 hour before paclitaxel, or Dexamethasone (Decadron) 20 mg PO given twice, at 12 and 6 hours before the paclitaxel
- Diphenhydramine (Benadryl) 50 mg IV once prior to paclitaxel
- One of the following H2 blockers:
- Cimetidine (Tagamet) 300 mg IV once prior to paclitaxel
- Ranitidine (Zantac) 50 mg IV once prior to paclitaxel
- Famotidine (Pepcid) 20 mg IV once prior to paclitaxel
- "The use of prophylactic granulocyte colony-stimulating factor was allowed but not required"
References
- Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12. link to original article contains verified protocol PubMed
VBM
back to top |
VBM: Vincristine, Bleomycin, Methotrexate
Regimen, Pizzocaro et al. 1988 & Pagliaro et al. 2009
The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."
Level of Evidence: 12-patient report
Limited information about this is available since Pizzocaro et al. 1988 is not available online, and Pagliaro et al. 2009 is a review article which does not include complete details about the regimen.
- Bleomycin (Blenoxane) 30 mg IM once per week
- Vincristine (Oncovin) 1 mg IV once per week
- Methotrexate (MTX) 30 mg PO once per week
12-week course
References
- Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. contains protocol PubMed
- Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. doi: 10.1007/s00345-008-0310-z. Epub 2008 Aug 6. link to original article contains verified protocol PubMed
Metastatic or unresectable disease
BMP, MPB
back to top |
BMP: Bleomycin, Methotrexate, Platinol
MPB: Methotrexate, Platinol, Bleomycin
Regimen #1, Haas et al. 1999 (SWOG 8520)
The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."
Level of Evidence: Phase II
- Bleomycin (Blenoxane) 10 units/m2 IV bolus once per day on days 1 & 8
- Chemotherapy with bleomycin was discontinued when a total cumulative dose of 200 units/m2 was reached
- Methotrexate (MTX) 25 mg/m2 IV bolus once per day on days 1 & 8
- Cisplatin (Platinol) 75 mg/m2 at a concentration of 1 mg/mL normal saline IV given at a rate of 1 mg/min once on day 1
21-day cycles, given until disease progression; patients who achieved complete remission discontinued therapy after 6 cycles
Supportive medications:
- Normal saline IV at 250 mL/hour, starting 1 hour before cisplatin and continued at least 6 hours after cisplatin.
- Furosemide (Lasix) 40 mg IV once prior to cisplatin
Regimen #2, Corral et al. 1998 & Pagliaro et al. 2009
The NCCN, Penile Cancer version 1.2013, says that "bleomycin-containing regimens were associated with unacceptable toxicity and are no longer recommended."
Level of Evidence: Phase II
21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy.
- Bleomycin (Blenoxane) 10 mg/m2 IV once per day on days 2 to 6 (note: Pagliaro et al. 2009 lists a "dosage of 50 mg/m2 on days 2-6," which could be misinterpreted as 50 mg/m2 for each dose, which is in contrast to the 50 mg/m2 for each cycle that Corral et al. 1998 describes.)
- Methotrexate (MTX) 200 mg/m2 IV once per day on days 1, 15, 22
- Folinic acid (Leucovorin) 25 mg PO every 6 hours x 12 doses, starting 24 hours after each dose of methotrexate
- Cisplatin (Platinol) 20 mg/m2 IV over 3 hours once per day on days 2 to 6 (note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m2.)
28-day cycles
References
- Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. link to original article contains verified protocol PubMed
- Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. link to original article contains verified protocol PubMed content property of HemOnc.org
- Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. doi: 10.1007/s00345-008-0310-z. Epub 2008 Aug 6. link to original article contains verified protocol PubMed
Cisplatin & Fluorouracil
back to top |
Regimen, Shammas et al. 1992
Level of Evidence: 8 patients reported, 2 with partial response
- Cisplatin (Platinol) 100 mg/m2 IV once once on day 1
- Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion on days 1 to 5
(unable to retrieve full article for further details)
References
- Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. contains protocol PubMed
Cisplatin & Irinotecan
back to top |
Regimen, Theodore et al. 2008 (EORTC 30992)
Level of Evidence: Phase II
- Cisplatin (Platinol) 80 mg/m2 IV over 1 to 3 hours once on day 1, given second
- Irinotecan (Camptosar) 60 mg/m2 IV over 30 minutes once per day on days 1, 8, 15, given first
28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease
Supportive medications:
- Adequate hydration with cisplatin, per guidelines at each investigator's site
- Antiemetic medication per routine local practice.
- "Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
References
- Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
back to top |
Regimen, Di Lorenzo et al. 2011
Level of Evidence: Phase II
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles, administered until disease progression or unacceptable toxicity
Supportive medications:
- G-CSF could be used in later cycles if the patient developed febrile neutropenia during treatment
- Dexamethasone (Decadron) 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel
References
- Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. link to original article contains verified protocol PubMed
Panitumumab (Vectibix)
back to top |
Regimen, Necchi et al. 2011
Necchi et al. 2011 is a case report referenced by the NCCN Guidelines, Penile Cancer version 1.2013.
Level of Evidence: Case report
- Panitumumab (Vectibix) 6 mg/kg IV once on day 1
14-day cycles
References
- Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. doi: 10.1200/JCO.2011.34.8367. Epub 2011 May 31. link to original article contains verified protocol PubMed
TIP
back to top |
No primary reference available, but the NCCN, Penile Cancer version 1.2013, says that "TIP is a reasonable first-line treatment for patients with metastatic penile cancer." (see neoadjuvant chemotherapy section)
TPF (Paclitaxel)
back to top |
TPF: Taxol, Platinol, Fluorouracil
Regimen, Pizzocaro et al. 2009
Level of Evidence: 6 patients reported
- Paclitaxel (Taxol) 120 mg/m2 in 500 mL 5% glucose solution IV once on day 1, given first
- Cisplatin (Platinol) 50 mg/m2 IV once per day on days 1 & 2
- Fluorouracil (5-FU) 1000 mg/m2/day in 2 liters half normal 2.5% glucose saline IV continuous infusion on days 2 to 5
21-day cycles; "two patients received more than the standard four courses"
Supportive medications:
- "Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
- "Antiemetic drugs and glutathione were administered before cisplatin"
- 1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after cisplatin
References
- Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. doi: 10.1016/j.eururo.2008.07.014. Epub 2008 Jul 14. link to original article contains verified protocol PubMed